DUROLANE

by

NASHA hyaluronic acid vs methylprednisolone for knee osteoarthritis: a prospective, multi-centre, randomized, noninferiority trial

Full list of Authors  
Leighton R, Åkermark C, Therrien R, Richardson JB, Andersson M, Todman MG, Arden NK.

[toggle]

Full AMA reference 
Leighton R., Åkermark C., Therrien R. et al. NASHA hyaluronic acid vs methylprednisolone for knee osteoarthritis: a prospective, multi-centre, randomized, non-inferiority trial. Osteoarthritis Cartilage. 2014; 22: 17-25.

Study Design
Level-I clinical study: prospective, multi-centre, randomized (1:1), corticosteroid controlled, double-blind.

Objective 
To compare in a non-inferiority trial the effectiveness and safety of a single intraarticular injection of NASHA® (DUROLANE®) with the commonly used steroid; Methyl Prednisolone Acetate (MPA).

Conclusion 
442 patients with knee OA were randomly assigned to a treatment group (221 DUROLANE, 221 MPA). Results were similar between MPA and DUROLANE between 6-18 weeks. However, there was a significant reduction in the responders from week 18-26 in the MPA group which was not observed in the DUROLANE group. In response to a second DUROLANE treatment at 26 weeks, sustained improvements were seen in WOMAC outcomes irrespective of initial treatment. No serious device related AEs were reported.

Click here to view abstract

[/toggle]

Bioventus

Summary of Indications for Use
DUROLANE (3 mL): Symptomatic treatment of mild to moderate knee or hip osteoarthritis. In addition, DUROLANE has been approved in the EU for the symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, shoulder, elbow, wrist, fingers, and toes.

DUROLANE SJ (1 mL): Symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, elbow, wrist, fingers, and toes.

Both DUROLANE and DUROLANE SJ are also indicated for pain following joint arthroscopy in the presence of osteoarthritis within 3 months of the procedure. There are no known contraindications
You should not use DUROLANE if you have infections or skin disease at the injection site. DUROLANE has not been tested in pregnant or lactating women, or children. .

Risks can include transient pain, swelling and/or stiffness at the injection site.

Full prescribing information can be found in product labeling (1mL / 3mL).

DUROLANE, Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC. NASHA is a registered trademark of Nestlé Skin Health S.A.

© 2017 Bioventus LLC.

Durolane-since-2001
*First introduced in the European Union in 2001.

To learn more about DUROLANE or for contact information, please select your location to continue.